

Jecko Thachil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1061544/publications.pdf>

Version: 2024-02-01

141
papers

8,855
citations

87888

38
h-index

45317

90
g-index

141
all docs

141
docs citations

141
times ranked

13302
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonovert disseminated intravascular coagulation (DIC) in pregnancy: a new scoring system for the identification of patients at risk for obstetrical hemorrhage requiring blood product transfusion. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022, 35, 242-257.	1.5	12
2	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 39-47.	3.8	39
3	Embolismâ€™The journey from a calendar to the clot via the Lordâ€™s prayer. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 538-539.	3.8	0
4	Practical treatment guidance for cancer-associated thrombosis â€™ Managing the challenging patient: A consensus statement. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103599.	4.4	6
5	DIC in Pregnancy â€™ Pathophysiology, Clinical Characteristics, Diagnostic Scores, and Treatments. <i>Journal of Blood Medicine</i> , 2022, Volume 13, 21-44.	1.7	37
6	Management of haemostatic complications of chimaeric antigen receptor Tâ€™cell therapy. <i>British Journal of Haematology</i> , 2022, 197, 250-259.	2.5	0
7	Hemostasis in tweeters. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 272-273.	3.8	0
8	Exploring the epidemiology of disseminated intravascular coagulation: protocol for the DANish Disseminated Intravascular Coagulation (DANDIC) Cohort Study. <i>BMJ Open</i> , 2022, 12, e062623.	1.9	0
9	ISTH guidelines for antithrombotic treatment in COVIDâ€™19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	3.8	100
10	D-dimersâ€™â€™Normalâ€™Levels versus Elevated Levels Due to a Range of Conditions, Including â€™D-dimeritis,â€™Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and COVID-19. <i>Seminars in Thrombosis and Hemostasis</i> , 2022, 48, 672-679.	2.7	12
11	A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place. <i>Journal of Neurology</i> , 2021, 268, 2390-2401.	3.6	4
12	Dual origins and dual roles for von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 308-309.	3.8	1
13	Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. <i>Acta Haematologica</i> , 2021, 144, 418-426.	1.4	17
14	Similarities in coagulation for turophiles and clottologists. <i>British Journal of Haematology</i> , 2021, 193, e43-e44.	2.5	1
15	Similarities and perspectives on the two Câ€™sâ€™Cancer and COVIDâ€™19. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1161-1167.	3.8	10
16	Are white blood cells white?. <i>British Journal of Haematology</i> , 2021, 193, e31-e32.	2.5	1
17	COVID-19 (SARS-CoV-2) in Non-Airborne body fluids: A systematic review & Meta-analysis. <i>Turkish Journal of Urology</i> , 2021, 47, 87-97.	1.3	10
18	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1003-1011.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Could bloodletting have helped?. QJM - Monthly Journal of the Association of Physicians, 2021, , .	0.5	0
20	You can bleed, you are on bloodâ€thinners!. Journal of Thrombosis and Haemostasis, 2021, 19, 1379-1380.	3.8	2
21	Lessons learnt from COVIDâ€19 coagulopathy. EJHaem, 2021, 2, 577-584.	1.0	12
22	Chronic anticoagulation is not associated with a reduced risk of acute kidney injury in hospitalised Covid-19 patients. BMC Nephrology, 2021, 22, 224.	1.8	8
23	The relation between fibrinogen level, neutrophil activity and nucleosomes in the onset of disseminated intravascular coagulation in the critically ill. Journal of Internal Medicine, 2021, 290, 922-927.	6.0	1
24	History of the word â€œpurpuraâ€ and its current relevance. Journal of Thrombosis and Haemostasis, 2021, 19, 2318-2321.	3.8	0
25	Heparin â€“ Messiah or Verschlimmbesserung?. Journal of Thrombosis and Haemostasis, 2021, 19, 2373-2382.	3.8	8
26	D-dimers: a most misunderstood test. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-5.	0.5	0
27	Thromboprophylaxis in COVID-19 â€“ Rationale and considerations. Advances in Biological Regulation, 2021, 81, 100819.	2.3	2
28	Why do patients with DIC bleed?. Journal of Thrombosis and Haemostasis, 2021, 19, 2630-2631.	3.8	0
29	D-Dimer and thrombosis in COVID-19. Indian Journal of Vascular and Endovascular Surgery, 2021, 8, 6.	0.1	0
30	Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal of Clinical Medicine, 2021, 10, 191.	2.4	83
31	D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients. Journal of Clinical Medicine, 2021, 10, 39.	2.4	20
32	Newly Proposed Sepsis-Induced Coagulopathy Precedes International Society on Thrombosis and Haemostasis Overt-Disseminated Intravascular Coagulation and Predicts High Mortality. Journal of Intensive Care Medicine, 2020, 35, 643-649.	2.8	60
33	Management of bleeding and procedures in patients on antiplatelet therapy. Blood Reviews, 2020, 39, 100619.	5.7	14
34	The authors reply. Critical Care Medicine, 2020, 48, e989-e990.	0.9	0
35	Hypoxiaâ€“An overlooked trigger for thrombosis in COVIDâ€19 and other critically ill patients. Journal of Thrombosis and Haemostasis, 2020, 18, 3109-3110.	3.8	37
36	ISTH DIC subcommittee communication on anticoagulation in COVIDâ€19. Journal of Thrombosis and Haemostasis, 2020, 18, 2138-2144.	3.8	69

#	ARTICLE	IF	CITATIONS
37	Myelofibrosis in ITP and with TPO-RA – time to rethink?. Platelets, 2020, 32, 1-2.	2.3	1
38	COVID-19 coagulopathy in pregnancy: Critical review, preliminary recommendations, and ISTH registry – Communication from the ISTH SSC for Women’s Health. Journal of Thrombosis and Haemostasis, 2020, 18, 3086-3098.	3.8	54
39	Differentiating biochemical from clinical heparin resistance in COVID-19. Journal of Thrombosis and Thrombolysis, 2020, 50, 1015-1016.	2.1	10
40	Reply to – Errors in the diagnosis for DIC due to a statistical misunderstanding – Journal of Thrombosis and Haemostasis, 2020, 18, 1792-1793.	3.8	3
41	Coagulopathy of Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1358-1364.	0.9	412
42	Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. British Journal of Haematology, 2020, 189, 1038-1043.	2.5	89
43	A proposal for staging COVID-19 coagulopathy. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 731-736.	2.3	82
44	SARS-2 Coronavirus – Associated Hemostatic Lung Abnormality in COVID-19: Is It Pulmonary Thrombosis or Pulmonary Embolism?. Seminars in Thrombosis and Hemostasis, 2020, 46, 777-780.	2.7	85
45	Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematology, the, 2020, 7, e438-e440.	4.6	1,186
46	Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 1859-1865.	3.8	547
47	Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin. Journal of Thrombosis and Haemostasis, 2020, 18, 2424-2425.	3.8	10
48	All those D-dimers in COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 2075-2076.	3.8	34
49	The need for accurate D-dimer reporting in COVID-19: Communication from the ISTH SSC on fibrinolysis. Journal of Thrombosis and Haemostasis, 2020, 18, 2408-2411.	3.8	49
50	The protective rather than prothrombotic fibrinogen in COVID-19 and other inflammatory states. Journal of Thrombosis and Haemostasis, 2020, 18, 1849-1852.	3.8	25
51	RE: The prothrombin time ratio is not a more effective marker for evaluating sepsis-induced coagulopathy than fibrin-related markers: Response to the Letter to the Editor by Dr Wada. Journal of Thrombosis and Haemostasis, 2020, 18, 1507-1509.	3.8	1
52	Coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 2103-2109.	3.8	453
53	The unique characteristics of COVID-19 coagulopathy. Critical Care, 2020, 24, 360.	5.8	366
54	ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis, 2020, 18, 1023-1026.	3.8	1,513

#	ARTICLE	IF	CITATIONS
55	The versatile heparin in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1020-1022.	3.8	343
56	Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 740-747.	3.8	56
57	Effects of the COVID-19 pandemic on supply and use of blood for transfusion. <i>Lancet Haematology</i> , the, 2020, 7, e756-e764.	4.6	216
58	What do monitoring platelet counts in COVID-19 teach us?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2071-2072.	3.8	66
59	Type and dose of heparin in Covid-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2063-2064.	3.8	19
60	DOACs and newer hemophilia therapies in COVID-19: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1795-1796.	3.8	17
61	Laboratory haemostasis monitoring in COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2058-2060.	3.8	25
62	Reporting of D-dimer data in COVID-19: some confusion and potential for misinformation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1191-1199.	2.3	94
63	Thrombomodulin in disseminated intravascular coagulation and other critical conditions—a multi-faceted anticoagulant protein with therapeutic potential. <i>Critical Care</i> , 2019, 23, 280.	5.8	79
64	Managing sepsis-associated coagulopathy remains an enigma. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1586-1589.	3.8	5
65	Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1989-1994.	3.8	325
66	The Elusive Diagnosis of Disseminated Intravascular Coagulation: Does a Diagnosis of DIC Exist Anymore?. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 100-107.	2.7	20
67	DIC in obstetrics: Diagnostic score, highlights in management, and international registry—communication from the DIC and Women's Health SSCs of the International Society of Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1562-1566.	3.8	25
68	Proposal of a two-step process for the diagnosis of sepsis-induced disseminated intravascular coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1265-1268.	3.8	37
69	The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. <i>Thrombosis Research</i> , 2019, 179, 11-14.	1.7	41
70	Modified ISTH pregnancy-specific DIC score in parturients with liver rupture: population-based case series. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019, 32, 2517-2523.	1.5	11
71	Reintroduction of anticoagulant therapy after intracranial haemorrhage: If and when?. <i>Blood Reviews</i> , 2018, 32, 256-263.	5.7	6
72	British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. <i>British Journal of Haematology</i> , 2018, 181, 54-67.	2.5	114

#	ARTICLE	IF	CITATIONS
73	A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 439-445.	1.7	40
74	The problem with incidental and chronic portal vein thrombosis. <i>European Journal of Internal Medicine</i> , 2017, 39, e29-e30.	2.2	3
75	Diagnosis of overt and non-overt disseminated intravascular coagulation: A survey among experts and a call for action from the ISTH. <i>Thrombosis Research</i> , 2017, 152, 74-76.	1.7	4
76	Mixing studies for abnormal coagulation screen – the current trend. <i>Clinical Chemistry and Laboratory Medicine</i> , 2017, 55, e54-e55.	2.3	4
77	Investigating easy bruising in an adult. <i>BMJ: British Medical Journal</i> , 2017, 356, j251.	2.3	5
78	The application of anticoagulant therapy to sepsis. <i>Journal of Intensive Care</i> , 2017, 5, 32.	2.9	5
79	Management of parturients with Factor XI deficiency – 10 year case series and review of literature. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 215, 85-92.	1.1	19
80	Portal vein thrombosis – a primer for the general physician. <i>Clinical Medicine</i> , 2017, 17, 212-219.	1.9	12
81	Platelets and infections in the resource-limited countries with a focus on malaria and viral haemorrhagic fevers. <i>British Journal of Haematology</i> , 2017, 177, 960-970.	2.5	11
82	How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?. <i>Blood Reviews</i> , 2017, 31, 151-157.	5.7	6
83	How do we approach thrombocytopenia in critically ill patients?. <i>British Journal of Haematology</i> , 2017, 177, 27-38.	2.5	83
84	New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. <i>BMJ Open</i> , 2017, 7, e017046.	1.9	230
85	D-Dimer Testing: Laboratory Aspects and Current Issues. <i>Methods in Molecular Biology</i> , 2017, 1646, 91-104.	0.9	49
86	Is protein C zymogen really ineffective for ALL cases of sepsis including septic DIC?. <i>Intensive Care Medicine</i> , 2017, 43, 152-153.	8.2	0
87	The Comparison of the Protective Effects of $\hat{1}\pm$ - and $\hat{1}^2$ -Antithrombin against Vascular Endothelial Cell Damage Induced by Histone in Vitro. <i>TH Open</i> , 2017, 01, e3-e10.	1.4	4
88	Harmonisation of D-dimer – A call for action. <i>Thrombosis Research</i> , 2016, 137, 219-220.	1.7	56
89	Antiplatelet therapy – a summary for the general physicians. <i>Clinical Medicine</i> , 2016, 16, 152-160.	1.9	36
90	Is antithrombin III for sepsis-associated disseminated intravascular coagulation really ineffective?. <i>Intensive Care Medicine</i> , 2016, 42, 1193-1194.	8.2	4

#	ARTICLE	IF	CITATIONS
91	The beneficial effect of acute phase increase in serum ferritin. <i>European Journal of Internal Medicine</i> , 2016, 35, e16-e17.	2.2	4
92	Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2016, 145, 46-50.	1.7	16
93	Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. <i>Critical Care</i> , 2016, 20, 287.	5.8	51
94	Supportive management strategies for disseminated intravascular coagulation. <i>Thrombosis and Haemostasis</i> , 2016, 115, 896-904.	3.4	65
95	Disseminated intravascular coagulation – new pathophysiological concepts and impact on management. <i>Expert Review of Hematology</i> , 2016, 9, 803-814.	2.2	39
96	Disseminated Intravascular Coagulation. <i>Anesthesiology</i> , 2016, 125, 230-236.	2.5	25
97	Ventilation perfusion scan or computed tomography pulmonary angiography for the detection of pulmonary embolism?. <i>European Journal of Internal Medicine</i> , 2016, 32, e26-e27.	2.2	4
98	Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. <i>International Journal of Hematology</i> , 2016, 103, 253-261.	1.6	53
99	Potential diagnostic markers for disseminated intravascular coagulation of sepsis. <i>Blood Reviews</i> , 2016, 30, 149-155.	5.7	41
100	Management of disseminated intravascular coagulation: A survey of the International Society on Thrombosis and Haemostasis. <i>Thrombosis Research</i> , 2015, 136, 239-242.	1.7	21
101	The use of fondaparinux in pregnancy. <i>British Journal of Haematology</i> , 2015, 168, 762-764.	2.5	19
102	The usefulness of antithrombin activity monitoring during antithrombin supplementation in patients with sepsis-associated disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2015, 135, 897-901.	1.7	27
103	The problem of pulmonary embolism diagnosis in pregnancy. <i>British Journal of Haematology</i> , 2015, 170, 727-728.	2.5	17
104	Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 452-463.	1.3	115
105	Vitamin B12 deficiency – A 21st century perspective. <i>Clinical Medicine</i> , 2015, 15, 145-150.	1.9	167
106	Platelets in Inflammatory Disorders: A Pathophysiological and Clinical Perspective. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 572-581.	2.7	47
107	Cerebral venous thrombosis – A primer for the haematologist. <i>Blood Reviews</i> , 2015, 29, 45-50.	5.7	32
108	Deep vein thrombosis. <i>Hematology</i> , 2014, 19, 309-310.	1.5	29

#	ARTICLE	IF	CITATIONS
109	Alternate considerations for current concepts in ITP. Hematology, 2014, 19, 163-168.	1.5	5
110	Has deep vein thrombosis become a new epidemic?. European Journal of Internal Medicine, 2014, 25, e96-e97.	2.2	1
111	Dispelling myths about coagulation abnormalities in internal medicine. Clinical Medicine, 2014, 14, 239-244.	1.9	3
112	What is the evidence for platelet transfusion thresholds?. European Journal of Internal Medicine, 2014, 25, e37.	2.2	1
113	Relevance of clotting screen requests. European Journal of Internal Medicine, 2014, 25, e111-e112.	2.2	1
114	Anticoagulation in chronic kidney disease patients--the practical aspects. CKJ: Clinical Kidney Journal, 2014, 7, 442-449.	2.9	104
115	Two Factor XI Concentrates Correct Impaired Thrombin Generation in Major FXI Deficiency but Are Not Equivalent in Their Effect. Blood, 2014, 124, 1519-1519.	1.4	1
116	Contact Activation Inhibition and Platelet Rich Plasma Are Required in Order to Differentiate Bleeders from Non-Bleeders in FXI Deficiency Using the Thrombin Generation Assay. Blood, 2014, 124, 696-696.	1.4	0
117	Why do thrombocytopenic patients bleed?. Transfusion, 2013, 53, 3280-3281.	1.6	1
118	Erythropoietin Corrects Thrombocytopenia. American Journal of Medicine, 2013, 126, e3-e4.	1.5	2
119	Thrombocytopenia in an adult. BMJ, The, 2013, 346, f3407-f3407.	6.0	3
120	Haemolysis secondary to intravenous immunoglobulins for ITP. Hematology, 2013, 18, 178-180.	1.5	3
121	Human CRP Defends against the Toxicity of Circulating Histones. Journal of Immunology, 2013, 191, 2495-2502.	0.8	102
122	Complete remission of refractory immune thrombocytopenia (<scp>ITP</scp>) with a short course of <scp>R</scp>omiplostim. European Journal of Haematology, 2013, 91, 376-377.	2.2	12
123	Thrombocytopenia and Thromboprophylaxis. Chest, 2013, 144, 1979.	0.8	0
124	Steroids and Arteriovenous Thrombosis. Chest, 2013, 143, 1836.	0.8	2
125	A practical approach to thrombophilia testing. British Journal of Hospital Medicine (London, England:) Tj ETQq1 1 0.784314 rgBT /Ove	0.5	2
126	Phenotypic implications of a co-existent haemorrhagic and thrombotic genotype. Blood Coagulation and Fibrinolysis, 2012, 23, 232-234.	1.0	1

#	ARTICLE	IF	CITATIONS
127	Current concepts in the management of disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2012, 129, S54-S59.	1.7	22
128	Recurrent venous thromboembolism while on anticoagulant therapy. <i>Blood Reviews</i> , 2012, 26, 175-181.	5.7	14
129	Clotting Screen Requests in Pediatrics. <i>Indian Journal of Pediatrics</i> , 2012, 79, 1233-1235.	0.8	0
130	Anemia “ The overlooked factor in bleeding related to liver disease. <i>Journal of Hepatology</i> , 2011, 54, 593-594.	3.7	20
131	A case of benign, multiple metastases. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 999-1000.	0.5	0
132	Thromboembolic events are not uncommon in patients with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2010, 150, 496-497.	2.5	26
133	Disseminated intravascular coagulation in obstetric disorders and its acute haematological management. <i>Blood Reviews</i> , 2009, 23, 167-176.	5.7	151
134	Heparin induced thrombocytopenia with thrombosis: a two step process?. <i>Hematology</i> , 2008, 13, 181-182.	1.5	3
135	The possible role of reticulocytes in sickle cell disease associated thromboembolism. <i>Hematology</i> , 2008, 13, 68-70.	1.5	3
136	The difficult distinction between haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 132-133.	2.9	0
137	Extreme Thrombocytosis-An Unusual Presentation of Inflammatory Bowel Disease. <i>Internal Medicine</i> , 2008, 47, 1255-1257.	0.7	5
138	Granulocytic sarcoma “ a rare presentation of a breast lump. <i>Annals of the Royal College of Surgeons of England</i> , 2007, 89, 7-9.	0.6	24
139	Nephrotic syndrome with spontaneous anticoagulant activity. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 624-626.	0.7	1
140	The problem with coagulopathy “. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	3.8	0
141	Anticoagulation in thrombocytopenic patients “ time to rethink?. <i>Journal of Thrombosis and Haemostasis</i> , 0, , .	3.8	2